A meta-analysis of ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Gruchy, Steven E; Fardy, John M
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS90
Academic Journal
An abstract of the article "A Meta-analysis of Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis," by Steven E. Gruchy and John M. Fardy is presented.


Related Articles

  • Ursodeoxycholic acid and primary biliary cirrhosis. Lim, A.G.; Northfield, T.C. // BMJ: British Medical Journal (International Edition);8/20/94-8/27/94, Vol. 309 Issue 6953, p491 

    Focuses on the use of ursodeoxycholic acid in primary biliary cirrhosis. Effects of the drug on the pathophysiology of the disease; Decrease in the retention of bile acids; Reduction in the damage caused by hydrophobic bile acids.

  • Ursodiol for Hepatobiliary Disorders. Rubin, Raymond A.; Kowalski, Thomas E.; Khandelwal, Mukul; Malet, Peter F. // Annals of Internal Medicine;8/1/94, Vol. 121 Issue 3, p207 

    Purpose: To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Data Sources: Personal databases of the authors and MEDLINE were...

  • Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity. Ouazzani-Chahdi, Amine; Elimadi, Aziz; Chabli, Allal; Spe´nard, Jean; Colin, Patrick; Haddad, Pierre S. // Canadian Journal of Physiology & Pharmacology;Feb2007, Vol. 85 Issue 2, p233 

    Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the effect of ursodeoxycholic acid and its NO-releasing derivative NCX-1000 alone or in combination with antioxidants on cultured mouse hepatocytes treated with amiodarone...

  • Ursodeoxycholic Therapy in Chronic Liver Disease: A Meta-Analysis in Primary Biliary Cirrhosis and in Chronic Hepatitis. Simko, Vlado; Michael, Shoukry; Prego, Veronica // American Journal of Gastroenterology;Mar1994, Vol. 89 Issue 3, p392 

    Objectives: to determine whether ursodeoxycholic acid (UDCA) is effective in improving primary biliary cirrhosis (PBC) or chronic hepatitis (CH). Methods: Meta-analysis (MA) was performed on nine papers and three abstracts describing PBC and on nine papers and two abstracts with CH that were...

  • Ursodeoxycholic Acid in the Treatment of Chronic Liver Disease. Cirillo, Nicholas W.; Zwas, Felice R. // American Journal of Gastroenterology;Sep1994, Vol. 89 Issue 9, p1447 

    Recent data have suggested that ursodeoxycholic acid (UDCA) is useful in the treatment of a variety of cholestatic and chronic liver diseases. Symptomatic and biochemical improvement have been observed in diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, and cystic...

  • Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems. Kondrackiene, Jurate; Kupcinskas, Limas; Chawla, Yogesh K. // World Journal of Gastroenterology;10/14/2008, Vol. 14 Issue 38, p5781 

    Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder. Maternal effects of ICP are mild; however, there is a clear association between ICP and higher frequency of fetal distress, preterm delivery, and sudden intrauterine fetal death. The cause of ICP...

  • Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment. Lucangioli, Silvia E.; Castaño, Gustavo; Contin, Mario D.; Tripodi, Valeria P. // Annals of Clinical Biochemistry;Jan2009, Vol. 46 Issue 1, p44 

    Background: The diagnosis and treatment of intrahepatic cholestasis of pregnancy (ICP) has important implications on fetal health. The biochemical parameter commonly used in the diagnosis of ICP is the determination of the concentration of total serum bile acids (TSBA). However, bile acid...

  • Effects of Ursodeoxycholic Acid on Hepatic Inflammation and Histological Stage in Patients with Primary Biliary Cirrhosis. Batts, Kenneth P.; Jorgensen, Roberta A.; Dickson, E. Rolland; Lindor, Keith D. // American Journal of Gastroenterology;Nov1996, Vol. 91 Issue 11, p2314 

    Objectives: Ursodeoxychotic acid (UDCA) has been reported to be of benefit in the treatment of primary biliary cirrhosis; however, the effects of UDCA on the histological features of primary biliary cirrhosis are uncertain. The goat of this study was to determine the histological effects of 2 yr...

  • Oral bile acids in cystic fibrosis-associated liver disease. Colombo, C.; Crosignani, A.; Apostolo, M. G.; Marzano, M. T.; Bettinardi, N.; Giunta, A. // Journal of the Royal Society of Medicine (Supplement);Jan1994, Vol. 87 Issue 21, p20 

    The article discusses the efficacy of ursodeoxycholic acid (UDCA) in the treatment of cystic fibrosis (CF)-associated liver disease. The natural history of CF-associated liver disease is explored. The benefits of using UDCA treatment in CF-associated liver disease are mentioned. Several clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics